-
公开(公告)号:US11278616B2
公开(公告)日:2022-03-22
申请号:US15932118
申请日:2016-08-03
Applicant: NITTO DENKO CORPORATION
Inventor: Kyohei Matsushita , Daisuke Asari , Takuya Shishido , Mitsuhiko Hori
Abstract: The present invention provides an immunity induction-promoting composition which has a track record of use as a medicine or medicinal additive and is capable of safely and effectively inducing cellular immune response, and a vaccine pharmaceutical composition containing the immunity induction-promoting composition. The present invention relates to an immunity induction-promoting composition containing an immunity induction promoter whose active ingredient is an antimicrobial drug.
-
2.
公开(公告)号:US10286067B2
公开(公告)日:2019-05-14
申请号:US15501271
申请日:2015-08-04
Applicant: NITTO DENKO CORPORATION
Inventor: Takuya Shishido , Daisuke Asari , Kyohei Matsushita , Mitsuhiko Hori
Abstract: The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.
-
公开(公告)号:US10092505B2
公开(公告)日:2018-10-09
申请号:US13737255
申请日:2013-01-09
Applicant: NITTO DENKO CORPORATION
Inventor: Daisuke Asari , Mitsuhiko Hori , Takuya Shishido
Abstract: The present invention provides an oral film-form base which has a rapid dissolution profile in the mouth and sufficient film strength, and gives an improved taking property by foaming in the mouth. The oral film-form base includes an edible polymer soluble both in water and in an organic solvent having a solubility parameter of 9.7 or higher, a foaming agent, and an auxiliary foaming agent, wherein the foaming agent is foamable in the presence of water, and the foaming agent and the auxiliary foaming agent each are insoluble in the organic solvent, have an average particle size of 0.1 to 60 μm, and are included in particle states.
-
公开(公告)号:US10471141B2
公开(公告)日:2019-11-12
申请号:US15507525
申请日:2015-09-02
Applicant: NITTO DENKO CORPORATION
Inventor: Takuya Shishido , Daisuke Asari , Mitsuhiko Hori
IPC: A61K38/00 , A61K39/00 , A61K39/395 , C07K16/28 , A61K31/198 , A61K39/39 , A61K31/663 , A61K47/54
Abstract: The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of humoral immunity against various antigens and exerting a high antibody production inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing humoral immunity, including: an antigen; and an immunity induction promoter that is a bisphosphonate.
-
5.
公开(公告)号:US10369219B2
公开(公告)日:2019-08-06
申请号:US15501271
申请日:2015-08-04
Applicant: NITTO DENKO CORPORATION
Inventor: Takuya Shishido , Daisuke Asari , Kyohei Matsushita , Mitsuhiko Hori
Abstract: The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.
-
公开(公告)号:US10076491B2
公开(公告)日:2018-09-18
申请号:US14166965
申请日:2014-01-29
Applicant: NITTO DENKO CORPORATION
Inventor: Daisuke Asari , Katsuyuki Okubo , Takuya Shishido , Arimichi Okazaki , Yoshiki Maeda , Kyohei Matsushita , Wenjing Li , Mitsuhiko Hori , Haruo Sugiyama
IPC: A61K39/00 , A61K39/02 , A61K45/06 , A01N63/00 , A61K31/7004 , A61K9/00 , A61K31/407 , A61K31/192 , A61K31/405 , A61K31/616 , A61K31/196 , A61K31/415 , A61K31/42 , A61K31/4035 , A61K31/353 , A61K31/5575 , A61K31/216 , A61K31/426 , A61K38/10 , A61K39/39
CPC classification number: A61K9/0014 , A61K31/192 , A61K31/196 , A61K31/216 , A61K31/353 , A61K31/4035 , A61K31/405 , A61K31/407 , A61K31/415 , A61K31/42 , A61K31/426 , A61K31/5575 , A61K31/616 , A61K38/10 , A61K39/0011 , A61K39/39 , A61K2039/54 , A61K2039/572
Abstract: The invention provides a vaccine composition containing an antigen for inducing cellular immunity, comprising at least one first cellular immunity induction promoter.
-
公开(公告)号:US09498527B2
公开(公告)日:2016-11-22
申请号:US13856002
申请日:2013-04-03
Applicant: NITTO DENKO CORPORATION , OSAKA UNIVERSITY
Inventor: Masahiro Fukasaka , Arimichi Okazaki , Daisuke Asari , Mitsuhiko Hori , Shizuo Akira , Osamu Takeuchi
IPC: A61K39/39 , A61K39/145 , A61K39/12 , A61K39/00
CPC classification number: A61K39/145 , A61K39/12 , A61K39/39 , A61K2039/5252 , A61K2039/541 , A61K2039/542 , A61K2039/55561 , A61K2039/55572 , A61K2039/575 , C12N7/00 , C12N2710/00034 , C12N2760/16034 , C12N2760/16134 , Y02A50/386 , Y02A50/41 , Y02A50/412
Abstract: An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.
Abstract translation: 提供可用于感染性疾病的预防或治疗剂,有效诱导全身免疫应答或粘膜免疫应答的口服给药的疫苗组合物。 一种用于给予人或动物口腔的疫苗组合物,所述疫苗组合物含有至少一种源自感染性疾病的抗原,以及至少一种选自toll样受体4(TLR4)激动剂 ,一种toll样受体2/6(TLR2 / 6)激动剂和环二核苷酸,或其衍生物或盐。
-
公开(公告)号:US09439872B2
公开(公告)日:2016-09-13
申请号:US14813797
申请日:2015-07-30
Applicant: NITTO DENKO CORPORATION
Inventor: Kyohei Matsushita , Daisuke Asari , Takuya Shishido , Mitsuhiko Hori
IPC: A61F13/02 , A61K9/70 , A23L1/30 , A23L1/305 , A61K38/00 , A61K9/00 , A61K47/36 , A61K9/20 , A61K31/48 , A61K31/7052 , A61K31/715 , A61K31/79 , A61K31/137 , A61K31/138 , A61K31/18 , A61K31/422 , A61K31/426 , A61K31/439 , A61K31/46 , A61K47/18 , A61K47/32 , A61K47/38
CPC classification number: A61K9/7007 , A23L33/13 , A23L33/17 , A23L33/175 , A23P10/00 , A61K9/00 , A61K9/0056 , A61K9/006 , A61K9/2054 , A61K9/70 , A61K9/7015 , A61K31/137 , A61K31/138 , A61K31/18 , A61K31/422 , A61K31/426 , A61K31/439 , A61K31/46 , A61K31/48 , A61K31/7052 , A61K31/715 , A61K31/79 , A61K38/00 , A61K47/10 , A61K47/183 , A61K47/32 , A61K47/36 , A61K47/38
Abstract: The present invention aims to provide an oral film-form base and an oral film-form preparation which have a rapid dissolution profile in the mouth and sufficient film strength, give a good tactile impression when handled with fingers and favorable texture and taste in the mouth, and are administrable to those who have limitation in carbohydrate intake. The present invention relates to an oral film-form base including an edible polymer soluble in water and an organic solvent having a solubility parameter of 9.7 or higher, and particles of at least one compound selected from the group consisting of amino acid, dipeptide, and nucleotide, the particles of at least one compound selected from the group consisting of amino acid, dipeptide, and nucleotide being dispersed in the state of particles in the oral film-form base.
Abstract translation: 本发明的目的是提供一种在口中具有快速溶出曲线并具有足够的膜强度的口腔膜形式基质和口腔膜形式制剂,在手指处理时具有良好的触觉,口中具有良好的质地和味道 并且对那些在碳水化合物摄入方面有限制的人群是可以管理的。 本发明涉及包含可溶于水的食用聚合物和溶解度参数为9.7以上的有机溶剂的口腔膜型基质,以及至少一种选自氨基酸,二肽和 核苷酸,选自氨基酸,二肽和核苷酸的至少一种化合物的颗粒以口腔膜形式的基质中的颗粒状态分散。
-
公开(公告)号:US10688120B2
公开(公告)日:2020-06-23
申请号:US15570851
申请日:2016-04-28
Applicant: NITTO DENKO CORPORATION
Inventor: Kyohei Matsushita , Masahiro Fukasaka , Takuya Shishido , Daisuke Asari , Katsuyuki Okubo , Mitsuhiko Hori
IPC: A61K31/739 , A61K39/39 , A61K39/00 , A61K39/02 , A61K39/35 , A61P37/02 , A61P37/08 , A61P11/02 , A61P11/06
Abstract: The present invention provides an allergy vaccine composition that is useful as a prophylactic or therapeutic agent for an allergic disease and can safely and effectively induce immune tolerance. The vaccine composition is to be administered to a human or animal with an allergic disease for the prevention or treatment of the allergic disease. The vaccine composition contains: an immunomodulator which is a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt of the lipopolysaccharide; and at least one allergen.
-
10.
公开(公告)号:US10471140B2
公开(公告)日:2019-11-12
申请号:US16388266
申请日:2019-04-18
Applicant: NITTO DENKO CORPORATION
Inventor: Takuya Shishido , Daisuke Asari , Kyohei Matsushita , Mitsuhiko Hori
IPC: C07K14/705 , C07K16/28 , C12Q1/68 , A61K39/395 , C07H21/02 , A61K39/39 , A61K39/00
Abstract: The present invention aims to provide a composition for promoting humoral immunity induction and a vaccine pharmaceutical composition that can be universally used for various antigens in inducing humoral immunity to antigens, contain a Th2 reaction promoter, and exerts a high humoral immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition containing an antigen for humoral immunity induction and at least one Th2 reaction promoter.
-
-
-
-
-
-
-
-
-